MedTrace Logo

Treatment of Atopic Dermatitis by a Full-Body Blue Light Device

NCT03085303 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2018-08-07

No results posted yet for this study

Summary

Multicentric, placebo-controlled, double-blinded, three-armed, prospective, randomized controlled trial.150 patients diagnosed with atopic dermatitis will be randomized to arm 1 (irradiation for 30min at 415nm wavelength), arm 2 (irradiation for 30min at 450nm wavelength), and arm 3 (irradiation for 30min at low-dose (placebo)). Irradiation will be scheduled 3 times a week for 8 weeks. Patients will be followed up for four weeks after the last irradiation.

Conditions

  • Dermatitis, Atopic

Interventions

DEVICE

Full Body Blue Light Device

Full body blue light irradiation (phototherapy) of atopic dermatitis patients.

Sponsors & Collaborators

  • University Hospital Goettingen

    collaborator OTHER

  • Philipps University Marburg

    collaborator OTHER

  • University Hospital, Geneva

    collaborator OTHER

  • Philips Electronics Nederland BV

    lead INDUSTRY

Principal Investigators

  • Michael Schoen, Prof · University Medical Center Göttingen, Clinic of Dermatology, Venereology and Allergology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-16
Primary Completion
2018-07-31
Completion
2018-07-31

Countries

  • Germany
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03085303 on ClinicalTrials.gov